Search

Tolfenamic acid

Tolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent. … [L1292] In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291]

Lorlatinib

It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018

Hydrocortisone phosphate

Tasimelteon

By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism … Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.

Ethyl macadamiate

Ethyl macadamiate is derived from Macadamia terifolia seed oil. It is a non-volatile ester of ethyl alcohol and the fatty acids.

Brodalumab

Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-sever...

Daclatasvir

It exerts its antiviral action by preventing RNA replication and virion assembly via binding to NS5A, a nonstructural phosphoprotein encoded by HCV. … Hepatitis C is an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

Betaprodine

(From Martindale, The Extra Pharmacopoeia, 30th ed, p1067) … An opioid analgesic chemically related to and with an action resembling that of meperidine, but more rapid in onset and of shorter duration.

Levorphanol

It is nearly as effective orally as by injection.

Reproxalap

Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis … [L32990] NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.[L32990]